Enzymatica comments on article in Dagens Medicin
Dagens Medicin is critizing in an article on February 10, 2021 one of the clinical studies, the so called ColdPrev I, which is part of the clinical evaluation data supporting the benefits of the product, that Enzymatica uses in the marketing of ColdZyme®. Enzymatica refuses the criticism and gives the comment below.ColdZyme is a very well-documented product, whose effect on common cold has been verified in both in vitro studies as well as in vivo studies. An in vitro study from 2017 showed that ColdZyme could deactivate over 90% of the known viruses that cause common colds. The ColdPrev I